Immunic Inc
NASDAQ:IMUX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (7), the stock would be worth $-5.51 (151% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -13.7 | $10.75 |
0%
|
| Industry Average | 7 | $-5.51 |
-151%
|
| Country Average | 19.3 | $-15.14 |
-241%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
$137.2m
|
/ |
Jan 2026
$-97.2m
|
= |
|
|
$137.2m
|
/ |
Dec 2026
$-49.1m
|
= |
|
|
$137.2m
|
/ |
Dec 2027
$-41.1m
|
= |
|
|
$137.2m
|
/ |
Dec 2028
$-20.8m
|
= |
|
|
$137.2m
|
/ |
Dec 2029
$-5.9m
|
= |
|
|
$137.2m
|
/ |
Dec 2030
$74.5m
|
= |
|
|
$137.2m
|
/ |
Dec 2031
$67.2m
|
= |
|
|
$137.2m
|
/ |
Dec 2032
$103.1m
|
= |
|
|
$137.2m
|
/ |
Dec 2033
$138.4m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| DE |
|
Immunic Inc
NASDAQ:IMUX
|
1.3B USD | -13.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
349.5B USD | 83.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183B USD | 23.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
160.4B USD | 18.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.3B USD | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 36.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.1B AUD | 29.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.8 |
| Median | 19.3 |
| 70th Percentile | 29.5 |
| Max | 8 582.9 |
Other Multiples
Immunic Inc
Glance View
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 55 full-time employees. The company went IPO on 2014-04-17. The firm is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The firm is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.
